Skip to content
lsd.com
CompletedN/A

Prospective Multicentre Study of the Use of Ketamine in the Treatment of Refractory Chronic Pain in the French CLCC

NCT04459234 · KETACANCER · Centre Leon Berard

Closed to entry
Status
Not accepting participants
Not applicable
Phase
81
Target enrolment
12
Study sites
Outside the US

What it is testing

Summary

The primary objective of this study is to describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of indication (neuropathic sequelae pains, morphine additional effect or morphine withdrawal, intensity, localisation…) and administration protocol (route, posology, duration, administration sequence, premedication). The secondary objectives are to evaluate in the context of cancer, the analgesic efficacy, the tolerance profile (biological and clinical toxicities) and the quality of life, including anxiety and depression. In addition, the described parameters will be evaluated as safety and efficacy predictive factors of the Ketamine in oncology.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of indication

    Measured over Up to 3 months after inclusion

  • Describe the administration practices of the antalgic Ketamine in French CLCC (Centre de Lutte Contre le Cancer) in terms of administration protocol

    Measured over Up to 3 months after inclusion

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Patient at least 18 years old at the day of consenting to the study * Patient followed for a solid tumour or a hematological malignancy (treated or under treatment) * Patient presenting cancer chronic pain or post cancer treatment pain * Patient followed by a CLCC's intractable chronic pain consultation or centre * Patient with an indication of 1st Ketamine course: * Analgesic treatment of cancer chronic pain * Analgesic treatment for a post-cancer treatment chronic pain * Help for withdrawal from opioid treatment prescribed for a chronic cancer pain * Patient not previously treated by Ketamine * Patient covered by a medical insurance * Patient and/or family did not decline data collection after complete information (information sheet) Exclusion Criteria: * Patient presenting chronic pains not related to cancer or its treatments * Patient with a proven psychotic history * Patient who is not fluent enough in French

Where

12 study sites

FacilityCityRegionCountry
Institut BergoniéBordeaux—France
Centre François BaclesseCaen—France
Centre Jean PerrinClermont-Ferrand—France
Centre Leon BerardLyon—France
Institut Paoli CalmettesMarseille—France
Institut de Cancérologie de MontpellierMontpellier—France
Institut CurieParis—France
Institut GodinotReims—France
Centre Eugène MarquisRennes—France
Institut Universitaire du Cancer (IUCT)Toulouse—France
Institut de Cancérologie de Lorraine Alexis VautrinVandœuvre-lès-Nancy—France
Institut Gustave RoussyVillejuif—France

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT04459234 on ClinicalTrials.gov →

Last updated in the registry 2023-09-11. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits

Substance